A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
PHASE1This is a single center, open label Phase 1 clinical trial in normal adult ...
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
PHASE2A phase 2a multicenter, randomized, double-blind, placebo-controlled multip...
Location
The Parkinson's & Movement Disorder Institute
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
PHASE2This is a multi-center, open label Phase 2a clinical trial in subjects with...
Location
Cevaxin - The Panama Clinic